SCHEMBL1888752

SCHEMBL1888752

[CH2][C@@H](CNC(=O)OCOC(=O)CCC)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.37
TSHR P16473 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2C9 P11712 3/20 0.37
CYP2C19 P33261 3/20 0.37
CYP3A4 P08684 2/20 0.37
MAPK1 P28482 2/20 0.37
MAPT P10636 2/20 0.36
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
HPGD P15428 2/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884157 1.00 L3MBTL1 (0.41) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1885017 0.85 MAPT (0.40) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884874 0.85 MAPT (0.40) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884726 0.83 MAPT (0.40) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884773 0.83 MAPT (0.40) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884816 0.82 MAPT (0.36) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884547 0.82 MAPT (0.36) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL2230623 0.82 LMNA (0.46) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1884159 0.78 SMN1; SMN2 (0.37) L3MBTL1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL1881879 0.76 HPGD (0.38) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS L3MBTL1 2410/4885MEN1 3461/4885KMT2A 1917/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS L3MBTL1 2410/4885MEN1 3461/4885KMT2A 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.